Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 6/20 | 0.54 |
| ▸ | SERPINC1 | P01008 | 3/20 | 0.41 |
| ▸ | FGF1 | P05230 | 2/20 | 0.39 |
| ▸ | BDNF | P23560 | 3/20 | 0.38 |
| ▸ | PTN | P21246 | 2/20 | 0.38 |
| ▸ | MDK | P21741 | 2/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | HPSE | Q9Y251 | 6/20 | 0.33 |
| ▸ | PF4 | P02776 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14977909 | 0.88 | F10 (0.41) | F10SERPINC1FGF1BDNFPTN | |
| SCHEMBL14817756 | 0.85 | F10 (0.69) | F10SERPINC1FGF1BDNFPTN | |
| SCHEMBL18061224 | 0.83 | F10 (0.57) | F10SERPINC1FGF1BDNFPTN | |
| SCHEMBL16656905 | 0.78 | F10 (0.63) | F10SERPINC1FGF1BDNFPTN | |
| SCHEMBL15996528 | 0.78 | F10 (0.43) | F10SERPINC1FGF1F2HPSE | |
| SCHEMBL15996518 | 0.78 | F10 (0.43) | F10SERPINC1FGF1F2HPSE | |
| SCHEMBL15996538 | 0.78 | F10 (0.43) | F10SERPINC1FGF1F2HPSE | |
| SCHEMBL16418325 | 0.77 | F10 (0.60) | F10SERPINC1FGF1BDNFPTN | |
| SCHEMBL16330427 | 0.77 | F10 (0.71) | F10SERPINC1FGF1BDNFPTN | |
| SCHEMBL12266894 | 0.77 | F10 (0.53) | F10SERPINC1FGF1BDNFPTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889853-B2 | Process for the preparation of disaccharides applied to heparin pentasaccharides | SCINOPHARM SINGAPORE PTE LTD. (SG) | 2014-11-18 | — | — | US | disclosed |
| US-20120083594-A1 | Process for the Preparation of disaccharides Applied to Heparin Pentasaccharides | SCINOPHARM SINGAPORE PTE LTD. (SG) | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083594-A1 | Process for the Preparation of disaccharides Applied to Heparin Pentasaccharides | HPSE, F11, FGB | F10 16/4885SERPINC1 10/4885FGF1 454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.